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Abstract
Background and Aims: Patients with active, steroid-dependent ulcerative colitis with insufficient 
response or intolerance to immunosuppressants and/or biologic therapies have limited treatment 
options. Adacolumn, a granulocyte/monocyte adsorptive apheresis device, has shown clinical 
benefit in these patients. This study aimed to provide additional clinical data regarding the safety 
and efficacy of Adacolumn in this patient subgroup.
Methods: This single-arm, open-label, multicentre trial [ART] was conducted at 18 centres across the 
UK, France, and Germany. Eligible patients were 18–75 years old with moderate-to-severe, steroid-
dependent active ulcerative colitis with insufficient response or intolerance to immunosuppressants 
and/or biologics. Patients received ≥ 5 weekly apheresis sessions with Adacolumn. The primary 
endpoint was clinical remission rate [clinical activity index ≤ 4] at Week 12.
Results: In all, 86 patients were enrolled. At Week 12, 33/84 [39.3%] of patients in the intention-
to-treat population achieved clinical remission, with 47/84 [56.0%] achieving a clinical response 
[clinical activity index reduction of ≥ 3]. Clinical remission was achieved in 30.0% of patients with 
previous immunosuppressant and biologic failure; steroid-free clinical remission and response 
were observed in 22.6% and 35.7% of these patients, respectively. Quality of life [Short Health 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For 
commercial re-use, please contact journals.permissions@oup.com
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The ART Trial: 12-week Interim Results 813
Scale] significantly improved at Week 12 [p < 0.0001]. The majority of adverse events were of mild/
moderate intensity.
Conclusions: At Week 12, Adacolumn provided significant clinical benefit in a large cohort of 
steroid-dependent ulcerative colitis patients with previous failure to immunosuppressant and/or 
biologic treatment, with a favourable safety profile. These results are consistent with previous 
studies and support Adacolumn use in this difficult-to-treat patient subgroup.
Key Words:  Ulcerative colitis; apheresis; adacolumn
1. Introduction
Ulcerative colitis [UC] is a chronic relapsing and remitting inflam-
matory condition of the colon affecting between 1 and 20 people 
per 100 000 population per year.1,2 Relapses present with symptoms 
such as abdominal pain, bloody diarrhoea, weight loss, and anaemia, 
all of which have a significant impact on quality of life.2
The therapeutic goal of UC treatments is to induce steroid-free 
clinical remission,3 with remission defined as the complete reso-
lution of symptoms; a response to treatment is defined as clinical 
improvement.2 Treatment typically follows an escalation or step-
up approach whereby additional therapies are added in order to 
induce and maintain remission. Common therapeutic agents used 
to control disease activity include 5-aminosalicylate [5-ASA] com-
pounds, steroids, immunosuppressants [thiopurines], calcineurin 
inhibitors [cyclosporine, tacrolimus], and biologic agents such as 
anti-tumour necrosis factor alpha [TNF-α] antibodies [infliximab, 
adalimumab] and the anti-adhesion molecule vedolizumab.3,4,5 There 
is, however, an urgent need for therapies for steroid-dependent and 
steroid-refractory moderate-to-severely active UC patients due to 
side effects, patient intolerance to existing treatments, and failure of 
previous treatments. After the failure of existing therapies, surgery is 
often the only remaining option for these patients.3
In this context, granulocyte and monocyte adsorptive [GMA] 
apheresis [Adacolumn®, Otsuka Pharmaceuticals] and granulocyta-
pheresis [GCAP; Cellsorba®, Asahi Medical] have emerged as non-
pharmacological treatments with few side effects.6,7,8 The mechanism 
of action of GMA apheresis consists of the selective removal of the 
cell populations involved in the induction and perpetuation of bowel 
inflammation from the peripheral blood [neutrophils, monocytes, and 
platelets] without affecting other cells such as lymphocytes and eryth-
rocytes.9 GMA has also been shown to modulate levels of proinflam-
matory cytokines such as TNF-α, interleukin [IL]-1β, IL-6, and IL-8, 
and reduces cell-surface levels of L-selectin, a molecule that plays a key 
role in initiating leukocyte adhesion to the vascular endothelium.10,11
The clinical efficacy of GMA apheresis has been demonstrated 
in several studies, with clinical remission and response rates compa-
rable to those seen with conventional therapies.12,13,14 Registry data 
have shown that in clinical practice, apheresis leads to long-term 
steroid-free clinical remission in up to one-third of steroid-depend-
ent UC patients.15 An open-label multicentre study of 39 patients 
with steroid-refractory chronic active UC found that five apheresis 
sessions with Adacolumn resulted in a 37.1% clinical remission rate 
at Week 6, with 28.6% of patients achieving endoscopic remission. 
The median total dose of systemic steroids decreased from 20.0 mg/
day at baseline to 15.0 mg/day at Week 6 [p < 0.05]. Quality of life as 
measured by the Inflammatory Bowel Disease Questionnaire [IBDQ] 
increased significantly by 24 points [p < 0.01].16
Further clinical data on Adacolumn in difficult-to-treat UC 
patients are, however, required in order to fully explore the role of 
this device in the management of patients for whom clinical guidelines 
do not provide additional guidance due to limited treatment options.
The ART study was designed to further evaluate the effective-
ness and safety of Adacolumn in patients with moderate-to-severe 
UC who had an inadequate response to, or lost response to, or were 
intolerant to immunosuppressants and/or a biologic therapy. We 
report here the 12-week interim results of the 96-week ART study.
2. Methods
2.1. Study design
The ART [Adacolumn in Refractory UC Patients Trial] study is a 
single-arm, open-label, multicentre, post-marketing device study 
[NCT01481142] conducted at 18 centres across the UK, France, 
and Germany in accordance with the guidelines established in the 
Declaration of Helsinki. ART is a 96-week study, consisting of a 
5-week treatment period and an additional optional 5-week treat-
ment period, with study evaluations at Weeks 12, 24, and 48, and an 
additional telephone contact at Week 96 [Figure 1a].
2.2 Patient population
Eligible patients were 18 to 75 years old with moderate-to-severe, 
steroid-dependent, refractory active UC with insufficient response 
or intolerance to immunosuppressants and/or biologic agents. 
Insufficient response was defined as clinical activity index [CAI] ≥ 6 
after 3 months of treatment with 2.5 mg/kg azathioprine or 1.5 mg/
kg 6-mercaptopurine or after 14 weeks of starting anti-TNF-α ther-
apy. Intolerance to previous therapies was defined as an allergic reac-
tion, pancreatitis, severe immunosuppression, a psychotic disorder, 
or any contraindication according the manufacturer’s package insert.
UC was documented by clinical symptoms, endoscopic findings, 
and histology. Disease severity and steroid dependence were defined 
according to the ECCO guidelines.2 Key inclusion criteria were UC 
CAI ≥ 6 and endoscopic activity index [EAI] ≥ 4,17 and adequate 
peripheral venous access for the completion of apheresis.
Exclusion criteria included history of hypercoagulation disor-
der, hypersensitivity or intolerance to apheresis procedures, heparin 
allergy, or previous heparin-induced thrombocytopenia.
Patients were required to give written informed consent before 
undergoing any study procedures.
2.3. Study procedures
Endoscopy was performed at screening to evaluate EAI. Patients 
were treated with once-weekly Adacolumn apheresis over 5 con-
secutive weeks; this could be extended for up to 10 once-weekly 
treatments dependent upon treatment response, at the discretion of 
the investigator. The treatment schedule followed the typical clinical 
approach for administering Adacolumn apheresis in patients with 
UC.18 Each apheresis session was performed at a 30 ml/min flow rate 
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for 60 min, with a final volume of 1.8 l of peripheral venous blood 
processed per session. Any eventual interruptions of apheresis were 
not to be included in the 60 min apheresis time period. A decrease 
in the dose of concomitant steroids was allowed during the study, if 
tapered down in suitable steps, at the discretion of the investigator.
2.4. Study objectives and outcomes
The primary objective of this study was to assess device efficacy, as 
measured by the primary endpoint of UC remission rate at Week 12, 
with remission defined as achieving a CAI score of ≤ 4. The second-
ary objectives were to observe and document device efficacy as meas-
ured by: UC response rate at Week 12, with response defined as a 
reduction in CAI of ≥ 3; steroid-free remission and response rates at 
Week 12; time to remission and response; time to steroid-free remis-
sion and response; change from baseline in CAI and EAI at Week 12; 
quality of life change at Week 12, as measured by the Short Health 
Scale for UC19; high-sensitivity C-reactive protein [hsCRP] levels at 
Week 12; and calprotectin levels at Week 12.
(a)
(b)
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•
•
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Demographics
History
Pregnancy test
Physical examination
CAI
EAI
Haematology
hsCRP
Coagulation
Vital signs
Concomitant
medications
Total population
Safety population
ITT population
PP population
Inclusion/exclusion
criteria
Week 0
SCREENING
Adacolumn
treatment period
Optional Adacolumn
treatment period A
S
S
E
S
S
M
E
N
T
S
Weeks 1-5
Q1W 60 min apheresis
30 mL/min ow rate
Q1W 60 min apheresis
30 mL/min ow rate
Q1W assessments:
CAI, haematology,
coagulation, vital signs,
concomitant medications,
AEs
Q1W assessments:
CAI, haematology, hsCRP,
coagulation, vital signs,
concomitant medications,
AEs
Physical examination
CAI
EAI
hsCRP
Vital signs
Qol
Concomitant
medications
AEs
Weeks 1/3/5: hsCRP
Weeks 1/5: Qol
Enrolled at the data cut-off
(n=86)
Excluded (n=1):
AE-inability to cannulate
Excluded (n=1):
AE-syncope during cannulation;
withdrawn by investigator after 3
repeated attempts
Excluded due major protocol
violations (n=20):
Corticosteroid increase (n=8),
<5 Adacolumn treatments (n=2),
premature termination before end
of full treatment period (n=1),
violation of exclusion criteria (n=2),
violation of inclusion criteria (n=8),
Received ≥1 Adacolumn treatment
(n=85)
Received ≥1 Adacolumn treatment and provided ≥1 valid
post-baseline CAI measurement
(n=84)
Patients from the ITT population who received ≥5
Adacolumn treatments or who were discontinued due to
lack of efcacy or an AE possibly related to treatment 
(n=64)
Weeks 6-10 Week 12
Weeks
24-96
ASSESSMENTS
Figure 1. Study design [a] and participant flow [b]. AE, adverse event; CAI, clinical activity index; EAI, endoscopic activity index; hsCRP, high sensitivity C-reactive 
protein; ITT, intention-to-treat; PP, per protocol; QoL, quality of life; Q1W, every week.
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Additional secondary objectives were to observe and document 
device safety as measured by: adverse events [AEs] and vital signs at 
each study visit; laboratory safety parameter changes [haemoglobin, 
red blood cell counts, white blood cell counts, platelets and coagula-
tion parameters] at screening, baseline, and every treatment visit; 
and physical examination findings at baseline and Week 12.
2.5. Statistical analysis
This interim analysis was performed on all patients enrolled in the 
ART study who had a baseline visit at least 12 weeks before the 
data cut-off of 1 July 2013. Only data collected until the end of 
the 12-week follow-up period were included. Descriptive summa-
ries were generated where appropriate for each of the primary and 
secondary outcomes. The summary for the primary efficacy variable 
includes absolute frequencies, rates [percentages], and exact 95% 
confidence intervals [CIs] for the rates [Pearson–Clopper intervals].
Efficacy endpoints were assessed in the intention-to-treat [ITT] 
population [defined as all patients with ≥1 treatment and ≥ 1 valid 
post-baseline CAI measurement] and the per-protocol [PP] popula-
tion [defined as all patients from the ITT population who received 
≥ 5 treatments or who discontinued due to lack of efficacy or due 
to an AE with at least possible relation to the study device or treat-
ment]. Remission rate at Week 12 was estimated within the ITT and 
PP populations, calculated by dividing the number of patients with 
remission by the total number of patients; all missing values were 
analysed as not showing remission. Time to remission and response 
and time to steroid-free remission and response were summarised 
using Kaplan–Meier estimates. The reference range for central cal-
protectin testing was 0–50 mg/kg. In addition, a 200 mg/kg clinical 
cut-off level was also used to assess the effects of GMA on calpro-
tectin levels in this interim analysis, as it is generally appreciated 
that in IBD patients a cut-off level for calprotectin of 50 mg/kg is not 
appropriate and may not reflect relevant inflammatory activity. The 
proportions of patients above and below the cut-off of 200 mg/kg 
were analysed using McNemar’s test. Safety endpoints were assessed 
in the safety population, defined as all patients with ≥ 1 treatment.
All analyses were performed using SAS® Software Version 9.1.3 
or later.
3. Results
3.1. Patient disposition
Patients were enrolled from 12 October 2011. As of the data cut-off 
date of 1 July 2013, 86 patients were enrolled and signed informed 
consent, and were included in the total population [Figure 1b]. The 
safety population included 85/86 [98.8%] patients who initiated 
≥ 1 Adacolumn apheresis treatment. Included in the ITT popula-
tion were the 84/86 [97.7%] patients who received ≥ 1 treatment 
and provided ≥ 1 valid post-baseline CAI measurement; 1 patient 
was excluded due to an AE [syncope during cannulation] and was 
withdrawn by the investigator; 64/86 [74.4%] patients received ≥ 5 
treatments or were discontinued due to lack of efficacy or an AE, 
and were included in the PP population; the remaining 20 [23.8%] 
patients were excluded from the PP population due to protocol vio-
lations [Figure 1b]. In the safety population, 79/85 patients [92.9%] 
received 5 apheresis treatments; 59/85 [69.4%] received 6 or more 
treatments.
Of the total population, 72/86 [83.7%] patients completed 
Week 12; 5/86 [5.8%] did not complete the mandatory treat-
ment period; and 9/86 [10.5%] withdrew after this period but 
before Week 12. Of the patients who did not complete Week 12, 
4/84 [4.7%] of patients withdrew due to an AE, 2/84 [2.3%] 
withdrew consent, and 4/84 [4.7%] were withdrawn at inves-
tigator’s discretion, due to worsening colitis or venous access 
problems.
3.2. Patient demographics and baseline 
characteristics
Patient demographics and baseline characteristics of the safety 
population are shown in Table  1. A majority of patients [63.5%] 
were male, with a mean age of 44.8  years; 37 patients had left-
sided disease and 42 had pancolitis; only one patient had proctitis 
[1.2% of all patients]. The majority of patients [71.8%] had mod-
erate UC, and one-fifth [20.0%] had severe UC. Nearly two-thirds 
Table 1. Summary of patient demographics and baseline charac-
teristics [safety population].
Characteristic N = 85
Age, years
 Mean [SD] 44.8 [14.2]
Weight, kg
 Mean [SD] 76.5 [18.9]a
Sex, n [%]
 Male 54 [63.5]
 Female 31 [36.5]
Ulcerative colitis severity, n [%]
 Mild 7 [8.2]
 Moderate 61 [71.8]
 Severe 17 [20.0]
Localisation of disease, n [%]2,28
 Left-sided 37 [43.5]
 Proctitis 1 [1.2]
 Pancolitis 42 [49.4]
 Other 5 [5.9]
Number of previous hospital admissions 
related to ulcerative colitis, n [%]
 0 25 [29.4]
 1 22 [25.9]
 2 12 [14.1]
 3 8 [9.4]
 ≥ 4 18 [21.2]
Number of ulcerative colitis episodes in the 
past 12 months, n [%]
 0 12 [14.1]
 1 10 [11.8]
 2 11 [12.9]
 Chronic active 52 [61.2]
Time since first diagnosis, months
 Mean [SD] 106.3 [108.9]
 Median [lower quartile, upper quartile] 70.0 [29.0, 123.0]
Incidence of insufficient responseb or  
intolerancec to medications, n [%]
 Any insufficient response or intolerance 85 [100.0]
 Immunosuppressant medication 83 [97.6]
 Anti-TNF-α treatment 37 [42.4]
 Immunosuppressants and anti-TNF-α treatment 30 [35.2]
SD, standard deviation; TNF-α, tumour necrosis factor alpha.
aN = 84.
bClinical activity index ≥ 6 after 3 months of treatment with 2.5 mg/kg 
azathioprine or 1.5 mg/kg 6-mercaptopurine or after 14 weeks from starting 
anti-TNF-α therapy.
cAllergic reaction, pancreatitis, severe immunosuppression, a psychotic dis-
order, or any contraindication according the manufacturer’s package insert.
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of patients [61.2%] had chronic active UC in the past 12 months. 
Nearly all patients [98.8%] used concomitant medications during 
the 12 weeks, with 67.1% using glucocorticoids; 97.6% and 42.4% 
of patients had previously failed on immunosuppressants or anti-
TNF-α therapies, respectively, and 35.2% had failed on both.
3.3. Ulcerative colitis remission rate
After Adacolumn treatment, 33/84 (39.3% [95% CI 28.8, 50.6]) 
and 24/64 37.5% [95% CI 25.7, 50.5]) of patients in the ITT and 
PP populations, respectively, achieved remission [primary endpoint; 
Table 2].
Remission rates were also analysed for the subgroups of patients 
who previously failed on other medications. Remission was achieved 
at Week 12 by 31/77 (40.3% [95% CI 29.2, 52.1]) of patients who 
failed on immunosuppressants, 10/36 (27.8% [95% CI 14.2, 45.2]) 
of patients who failed on anti-TNF-α treatment, and 9/30 (30.0% 
[95% CI 14.7, 49.4]) of patients who failed on both immunosup-
pressants and anti-TNF-α treatment.
3.4. Ulcerative colitis response rate
After Adacolumn treatment, 47/84 (56.0% [95% CI 44.7, 66.8]) 
and 34/64 (53.1% [95% CI 40.2, 65.7]) of patients in the ITT and 
PP populations, respectively, achieved a clinical response [Table 2].
When analysed by subgroups, 44/77 (57.1% [95% CI 45.4, 
68.4]), 14/36 (38.9% [95% CI 23.1, 56.5]), and 12/30 (40.0% [95% 
CI 22.7, 59.4]) of patients who failed on immunosuppressants, 
anti-TNF-α treatment, or both therapies, respectively, achieved a 
response.
The Kaplan–Meier plots shows the time to remission [Figure 2a] 
and response [Figure 2b] for the ITT population; median estimates 
of time to remission and response were 43 days [95% CI 29, 63] 
and 24 days [95% CI 20, 34], respectively. Kaplan–Meier estimates 
of patients in remission and response at any time point were 52/84 
[61.9%] and 66/84 [78.6%], respectively. Results were similar for 
the PP population.
3.5. Additional secondary efficacy outcomes
Other secondary outcomes at Week 12 included steroid-free remis-
sion and response, and CAI and EAI change from baseline [Table 2]. 
Adacolumn treatment resulted in 22.6% and 35.7% of patients in 
the ITT population achieving steroid-free remission and response, 
respectively, at Week 12. These patients also experienced mean 
reductions in CAI and EAI of 3.4 and 2.2, respectively, at Week 12. 
Results were similar between the ITT and PP populations [Table 2].
Time to steroid-free remission and response for the ITT popula-
tion is shown in Figure  3; at any time point, 28/84 [33.3%] and 
36/84 [42.9%] of patients were in steroid-free remission or response.
A continued reduction in steroid use was observed during the 
study, with 32/84 [38.1%] patients steroid-free at Week 1 compared 
with 39/71 [54.9%] at Week 12. Mean steroid dose equivalent also 
decreased, from 14.7 mg at Week 1 to 9.5 mg at Week 12. Similar 
results were observed for the PP population.
Inflammatory activity at enrolment was confirmed in the ITT 
population by the median baseline hsCRP of 8.4 mg/l, with 51.8% 
of patients formally above the reference range. Median hsCRP 
decreased throughout the study to 5.3 mg/l at Week 12, with 36.2% 
formally above the reference range; however, this change was not 
statistically significant [p = 0.4303]. Similar results were observed 
for the PP population. Calprotectin levels numerically decreased 
relative to baseline; in the ITT population, median levels were 
771.5 mg/kg at Week 1 with 94.6% of patients formally above the 
reference range, and 499 mg/kg at Week 12 with 86.6% of patients 
formally above the reference range. Correspondingly, the percent-
ages of patients above the 200 mg/kg cut-off value decreased from 
89.0% at baseline to 75.0% at Week 12. McNemar’s test of paired 
proportions found that the percentage of patients below the cut-off 
increased significantly from baseline to Week 12 [p = 0.0325].
Quality of life improved from baseline to Week 12 [Table  3], 
with reductions in all four parameters of the Short Health Scale. The 
largest reduction was observed for the ‘bowel disease affecting daily 
activities’ parameter, with a mean 22.2% reduction from baseline to 
Week 12. The results of a repeated measures analysis of covariance 
model indicated a significant effect in change from baseline for all 
four parameters [p < 0.0001]. Similar results were observed for the 
PP population.
3.6. Safety evaluation
The majority of AEs experienced by patients were mild or moderate. 
Overall, 61/85 [71.8%] patients in the safety population experienced 
≥ 1 AE during the treatment-emergent period [from study start-up 
to 2 weeks after the last treatment], and 8/72 [11.1%] experienced 
≥ 1 AE during the follow-up period until Week 12 [Table  4]. No 
deaths occurred during the study. 6/85 [7.1%] patients experienced 
a serious adverse event [SAE]: UC, 4/85 [4.7%]; anal abscess, 1/85 
[1.2%]; cytomegalovirus infection, 1/85 [1.2%]. None of these SAEs 
were considered related to study treatment according to the study 
investigators. The most frequent treatment-emergent adverse events 
[TEAEs] by MedDRA preferred term were headache [20.0%], colitis 
ulcerative [11.8%], and poor venous access [10.6%] [Table 5].
Mean changes in haemoglobin from baseline through Week 
10 ranged from -0.21 to -0.44 g/dl; however, no clinically signifi-
cant changes were observed at Week 12 compared with baseline. 
The number of platelets decreased from baseline at every visit, not 
Table 2. Summary of efficacy outcomes at Week 12.
Outcome ITT population 
[N = 84]
PP population 
[N = 64]
Remission [CAI of ≤ 4]
 n [%] 33 [39.3] 24 [37.5]
 95% CI 28.8, 50.6 25.7, 50.5
Response [CAI reduction ≥ 3]
 n [%] 47 [56.0] 34 [53.1]
 95% CI 44.7, 66.8 40.2, 65.7
Steroid-free remission
 n [%] 19 [22.6] 15 [23.4]
 95% CI 14.2, 33.1 13.8, 35.7
Steroid-free response
 n [%] 30 [35.7] 23 [35.9]
 95% CI 25.6, 46.9 24.3, 48.9
CAI score change from baseline
 N 70 52
 Mean [SD] -3.4 [3.6] -3.4 [3.7]
 Minimum, maximum -11.0, 4.0 -11.0, 4.0
 95% CI -4.3, -2.6 -4.5, -2.4
EAI score change from baseline
 N 64 52
 Mean [SD] -2.2 [3.5] -2.4 [3.2]
 Min, max -10, 6.0 -10.0, 4.0
 95% CI -3.0, -1.3 -3.3, -1.5
CAI, clinical activity index; CI, confidence interval; EAI, endoscopic activity 
index; ITT, intention-to-treat; PP, per protocol; SD, standard deviation.
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exceeding a maximum change of -28.8 x 109/l at Week 7. There were 
no clinically significant shifts in other laboratory parameters or in 
vital signs. There were no colectomies during the treatment-emer-
gent period and there was one during the follow-up period.
5.4. Discussion
UC is a debilitating chronic disease that often affects young patients. 
Not all patients respond to biologic therapy, which can be associ-
ated with significant side effects. Our 12-week interim results from 
a large cohort of such UC patients show a treatment benefit with 
Adacolumn in UC patients with limited other therapeutic options. 
Nearly 40% of the patients in this trial achieved remission at Week 
12 and over half achieved a response; furthermore, 23% of patients 
achieved steroid-free remission, with 36% achieving steroid-free 
response. Additional outcomes such as quality of life, CAI, and EAI 
also improved at Week 12 relative to baseline. The levels of calpro-
tectin, which serve as a marker of inflammation,20 also decreased 
over the course of the study. The majority of AEs were of mild or 
moderate intensity, and no new safety signals were observed.
The results of this interim analysis are consistent with previous 
studies; a pooled meta-analysis of seven randomised controlled trials 
showed that response or remission was achieved more often in UC 
patients treated with GMA [risk reduction 1.41; p = 0.01] than in 
patients treated with conventional therapy, and that after 12 weeks 
significantly higher remission rates were observed (risk reduction 
1.22 [95% CI 1.04, 1.43]).12 Another meta-analysis demonstrated 
a significantly improved response rate (odds ratio 2.88 [95% CI 
1.60, 5.18]) and remission rate (odds ratio 2.04 [95% CI 1.36, 
3.07]) as a result of GMA apheresis compared with conventional 
pharmacotherapy in patients with active moderate-to-severe UC.14 
In a systematic review of the clinical trial literature, it was shown 
that GMA apheresis appears to be of some benefit in moderate-
to-severe UC,13 suggesting further randomised controlled trials are 
required in patients with active disease. In a randomised controlled 
trial enrolling a moderate-to-severe steroid-dependent/refractory UC 
population, the non-inferiority of 5 and 10 Adacolumn treatments 
was established after 12 weeks, with clinical remission observed 
in 44% and 40% of patients, respectively.21 These data are in con-
trast to a randomised trial of Adacolumn, in which patients with 
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Figure 2. Time to [a] remission and [b] response for the ITT population. ITT, intention-to treat.
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moderate-to-severe active UC received either Adacolumn or sham 
apheresis for 9 weeks. Clinical response was observed in 44% of 
Adacolumn-treated patients and 39% of sham-treated patients, 
a difference that was not statistically significant. However, a post 
hoc analysis found significant differences in clinical remission and 
response in patients with modified Riley scores of 7, denoting histo-
logically active disease with erosions or ulcerations.22 This suggests 
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Figure 3. Time to [a] steroid-free remission and [b] steroid-free response for the ITT population. ITT, intention-to-treat.
Table 3. Quality of life change from baseline to Week 12 in the ITT 
population [N = 85].
Parameter n Mean [SD] Min, max 95% CI
Symptoms from bowel 
disease
65 -19.0 [33.7] -80.0, 93.0 -27.4, -10.7
Bowel disease affecting 
daily activities
65 -22.2 [33.9] -87.0, 90.0 -30.6, -13.8
Bowel disease causing 
worry
65 -11.7 [29.7] -70.0, 90.0 -19.1, -4.4
General well-being 65 -15.0 [33.0] -98.0, 62.0 -23.2, -6.8
CI, confidence interval; ITT, intention-to-treat; SD, standard deviation; 
min, minimum; max, maximum.
Table 4. Summary of adverse events experienced in the study.
n [%] Treatment-emergent 
period [N = 85]
Follow-up period 
[N = 72]
Patients with ≥ 1 AE 61 [71.8] 8 [11.1]
Patients with ≥ 1 SAE 6 [7.1] 0 [0]
Patients with ≥ 1 possibly 
treatment-related AE
27 [31.8] 0 [0]
Patients with ≥ 1 treatment- 
related SAE
0 [0] 0 [0]
Patients with ≥ 1 treatment- 
related AE leading to discon-
tinuation of study treatment
16 [18.8] 0 [0]
Deaths 0 [0] 0 [0]
AE, adverse event; SAE, serious adverse event.
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that the effect of apheresis is more apparent in UC patients with 
active disease.23
Since other therapies such as anti-TNF-α are associated with risk 
of serious infections, lymphoma, and associated mortality,3,24,25 the 
favourable safety profile of Adacolumn as observed in the past and in 
present studies may therefore be of benefit in these patients. Common 
fears of patients with ulcerative colitis include adverse events associ-
ated with medications, which can affect adherence to treatments.26,27 
GMA itself is not without adverse events; in previous studies, shiver-
ing, nausea, headaches, ‘flushing’, and fever have been reported in 
5–33% of treated patients.7 The most common treatment-emergent 
adverse event observed in the present study was headache. Due to 
the nature of GMA, vascular access adverse events pose a potential 
problem for treatment administration; in this study, 8.2% of patients 
experienced vascular access complications, defined as the inability to 
cannulate or no flow. The events observed in this study were however 
mild-to-moderate; a non-drug therapy such as Adacolumn with this 
safety profile may be an attractive option for patients.
The ART population was composed of patients who are difficult 
to treat and for whom the current clinical guidelines are of less use 
due to a paucity of therapeutic options. A limitation of this study was 
the single-arm design, meaning that statistical comparisons could not 
be performed. A placebo control would have been included under 
ideal circumstances, but the clinical setting of the patient population 
provided the rationale for the ART study design, due to the difficulty 
of performing randomised trials in patients with urgent medical need. 
Positive data have been produced from clinical trials of anti-TNF-α 
therapies, with long-term steroid-free remission rates of 26% and 
13.3% at 12 months,3 and vedolizumab every 8 weeks in patients 
with moderate-to-severe UC which resulted in 12-month remission 
and steroid-free remission rates of 42% and 31%, respectively.5 
However, despite these data there still exists a sizeable population of 
patients that require effective treatment because of a lack of response 
to these drugs; results from the full 96-week ART study will provide 
insight into the long-term effectiveness of Adacolumn treatment.
In conclusion, Adacolumn treatment provided a positive and safe 
clinical benefit in terms of UC remission and response after 12 weeks 
in a difficult-to-treat patient subgroup who have limited effective 
treatment options.
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